Clinical Trials · NCT07357740
A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes
- Phase
- Phase 2
- Recruitment status
- Withdrawn
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 0
- Start date
- Aug 2026
- Locations
- 61 sites, 8 countries
- Primary endpoint
- Change in glycated haemoglobin (HbA1c)